GLTO

Galecto, Inc.

GLTO | $0.72 4.71% 77K

(0.0% 1d) (-11.2% 1m) (-67.0% 1y) (-5.6% 2d) (1.5% 3d) (-1.1% 7d) (-28.77% volume)
Earnings Calendar: 2022-08-04
Market Cap: $ 19,521,142
http://www.galecto.com
Sec Filling | Patents | 21 employees

Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. Its product portfolio includes GB0139, GB1211, GB2064, and GB1211. The company was founded by Ulf Nilsson, Hakon Leffler, Tariq Sethi, and Hans T. Schambye in 2011 and is headquartered in Copenhagen, Denmark.

cancer liver cirrhosis liver galectin-3 msa

add to watch list Paper trade email alert is off

Press-releases

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
Published: 2023-12-21 (Crawled : 21:00) - globenewswire.com
GLTO | $0.72 4.71% 77K

Health Technology

| 9.75% | O: -3.16% H: 14.98% C: 5.9%
fibrosis topline bone trial results

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
Published: 2023-10-23 (Crawled : 12:00) - globenewswire.com
GLTO | $0.72 4.71% 77K

Health Technology

| 19.89% | O: 2.26% H: 4.29% C: -1.72%
congress update trial

Galecto Announces Plans to Explore Strategic Alternatives
Published: 2023-09-26 (Crawled : 20:00) - globenewswire.com
GLTO | $0.72 4.71% 77K

Health Technology

| 19.09% | O: 27.5% H: 3.02% C: -4.12%

Galecto to Present at Investor Conferences in September
Published: 2023-08-31 (Crawled : 15:00) - globenewswire.com
GLTO | $0.72 4.71% 77K

Health Technology

| 16.84% | O: 1.37% H: 10.0% C: 2.54%

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
Published: 2023-08-15 (Crawled : 12:00) - globenewswire.com
GLTO | $0.72 4.71% 77K

Health Technology

| -70.94% | O: -67.95% H: 44.0% C: -10.2%
gb0139 treatment fibrosis topline trial results

Galecto Reports Second Quarter Operating and Financial Results
Published: 2023-07-31 (Crawled : 20:00) - globenewswire.com
GLTO | $0.72 4.71% 77K

Health Technology

| -77.92% | O: 2.6% H: 0.95% C: -11.39%
financial results

Galecto Set to Join Russell Microcap® Index
Published: 2023-06-20 (Crawled : 13:00) - globenewswire.com
LDNXF | $114.532 -12.32% 1.3K

Finance

| -1.4% | O: -0.3% H: 0.0% C: -1.26%
LNSTY | $28.4758 0.53% 99K

Finance and Insurance

| -0.32% | O: -1.45% H: 0.87% C: 0.18%
GLTO | $0.72 4.71% 77K

Health Technology

| -76.06% | O: -1.41% H: 0.0% C: -3.57%
microcap index set

Galecto to Present at the Upcoming Jefferies Healthcare Conference
Published: 2023-05-30 (Crawled : 12:00) - globenewswire.com
GLTO | $0.72 4.71% 77K

Health Technology

| -69.64% | O: 1.79% H: 2.19% C: 0.88%
conference

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis
Published: 2023-05-23 (Crawled : 12:20) - globenewswire.com
GLTO | $0.72 4.71% 77K

Health Technology

| -74.44% | O: 3.01% H: 1.46% C: -2.74%
gb0139 fibrosis trial

Galecto to Present Poster at Upcoming ATS 2023 International Conference
Published: 2023-05-17 (Crawled : 20:00) - globenewswire.com
GLTO | $0.72 4.71% 77K

Health Technology